Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Varsha Gandhi, PhD, on Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Sep
18
Today In Oncology
Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types
Do the Benefits of Fluoropyrimidine for GI Cancers Outweigh Cardiovascular Risk
Outcomes of Oncologic Extended Resection for Gallbladder Cancer Results of a Global Analysis
Chronic Toxicity Rates With De-escalated vs Standard Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Oral Microbiota and Risk for Pancreatic Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo